{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T02:59:16Z","timestamp":1777777156044,"version":"3.51.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001734","name":"Copenhagen University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001734","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>It remains undetermined whether gastrointestinal bleeding (GIB) associated with direct oral anticoagulant (DOAC) or vitamin K antagonists (VKA) is more severe.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In Danish nationwide registries, we identified patients with atrial fibrillation (AF) treated with anticoagulation with gastrointestinal bleeding (GIB). Logistic regression models were used to compare GIB severity between DOAC and VKA users, defined by 1. red blood cell transfusion or in-hospital death and 2. endoscopies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>From 2012\u20132018, 6,784 anticoagulated AF patients with GIB were identified; 3,724 patients VKA users and 3,060 DOAC (apixaban, dabigatran or rivaroxaban) users. The proportion of upper GIB was 49% in VKA users and 40.1% in DOAC users.\u00a0Blood transfusions were administered to 58.2% and 43.8\u201348.9% of patients with VKA and DOAC, respectively. Odds ratios (OR, adjusted for age, sex, and comorbidities) for severe GIB were significantly reduced for all DOACs compared to VKA (apixaban 0.71 (95% confidence interval (CI) 0.59\u20130.85), dabigatran 0.64 (95% CI 0.55\u20130.75) and rivaroxaban 0.69 (95% CI 0.59\u20130.81)).\u00a0Odds for endoscopy was significantly reduced in apixaban (OR 0.77 (95% CI 0.65\u20130.90) and dabigatran (OR 0.81 (95% CI 0.71\u20130.93) compared to VKA, and borderline reduced for rivaroxaban (OR 0.88 (95% CI 0.77\u20131.02)).\u00a0In patients with upper GIB, compared to VKA the use of gastroscopy was significantly reduced for apixaban (0.68 (95% CI 0.53\u20130.87)) but not for dabigatran or rivaroxaban.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>VKA use was associated with more severe GIB and more frequent endoscopies compared to DOAC. Future studies should identify subgroups at particular risk of severe GIB.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11606-026-10425-3","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T18:47:16Z","timestamp":1777488436000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Severity of Gastrointestinal Bleeding in Anticoagulant Therapy with Vitamin K Antagonist or Direct Oral Anticoagulant Therapy"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0330-8997","authenticated-orcid":false,"given":"Christine Benn","family":"Christiansen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia A.","family":"Henriksen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakob","family":"Burcharth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morten","family":"Lamberts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emil","family":"Fosb\u00f8l","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jawad Haider","family":"Butt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunnar","family":"Gislason","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Torp-Pedersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"issue":"1","key":"10425_CR1","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1186\/s12889-022-14403-2","volume":"22","author":"H Li","year":"2022","unstructured":"Li H, Song X, Liang Y, et al. Global, regional, and national burden of disease study of atrial fibrillation\/flutter, 1990-2019: results from a global burden of disease study, 2019. BMC Public Health. 2022;22(1):2015. https:\/\/doi.org\/10.1186\/s12889-022-14403-2.","journal-title":"BMC Public Health."},{"key":"10425_CR2","doi-asserted-by":"publisher","unstructured":"Van Gelder IC, Rienstra M, Bunting KV, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. Published online August 30, 2024:ehae176. https:\/\/doi.org\/10.1093\/eurheartj\/ehae176.","DOI":"10.1093\/eurheartj\/ehae176"},{"key":"10425_CR3","doi-asserted-by":"publisher","first-page":"31477","DOI":"10.1038\/srep31477","volume":"6","author":"L Staerk","year":"2016","unstructured":"Staerk L, Fosb\u00f8l EL, Gadsb\u00f8ll K, et al. Non-vitamin K antagonist oral anticoagulation usage according to age among patients with atrial fibrillation: Temporal trends 2011-2015 in Denmark. Sci Rep. 2016;6:31477. https:\/\/doi.org\/10.1038\/srep31477.","journal-title":"Sci Rep."},{"issue":"12","key":"10425_CR4","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-1151. https:\/\/doi.org\/10.1056\/NEJMoa0905561.","journal-title":"N Engl J Med."},{"issue":"10","key":"10425_CR5","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-891. https:\/\/doi.org\/10.1056\/NEJMoa1009638.","journal-title":"N Engl J Med."},{"issue":"22","key":"10425_CR6","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","volume":"369","author":"RP Giugliano","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093-2104. https:\/\/doi.org\/10.1056\/NEJMoa1310907.","journal-title":"N Engl J Med."},{"issue":"9921","key":"10425_CR7","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","volume":"383","author":"CT Ruff","year":"2014","unstructured":"Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. The Lancet. 2014;383(9921):955-962. https:\/\/doi.org\/10.1016\/S0140-6736(13)62343-0.","journal-title":"The Lancet."},{"issue":"5","key":"10425_CR8","doi-asserted-by":"publisher","first-page":"573.e9","DOI":"10.1016\/j.amjmed.2017.11.007","volume":"131","author":"MM Brodie","year":"2018","unstructured":"Brodie MM, Newman JC, Smith T, Rockey DC. Severity of Gastrointestinal Bleeding in Patients Treated with Direct-Acting Oral Anticoagulants. Am J Med. 2018;131(5):573.e9-573.e15. https:\/\/doi.org\/10.1016\/j.amjmed.2017.11.007.","journal-title":"Am J Med."},{"issue":"12","key":"10425_CR9","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.3390\/jcm10122693","volume":"10","author":"AR Choe","year":"2021","unstructured":"Choe AR, Moon CM, Tae CH, et al. Characteristics, Location, and Clinical Outcomes of Gastrointestinal Bleeding in Patients Taking New Oral Anticoagulants Compared to Vitamin K Antagonists. J Clin Med. 2021;10(12):2693. https:\/\/doi.org\/10.3390\/jcm10122693.","journal-title":"J Clin Med."},{"issue":"2","key":"10425_CR10","doi-asserted-by":"publisher","first-page":"222","DOI":"10.3164\/jcbn.20-140","volume":"69","author":"K Kirita","year":"2021","unstructured":"Kirita K, Kodaka Y, Shibata Y, et al. Impact of clinical characteristics of colonic diverticular bleeding in extremely elderly patients treated with direct oral anti-coagulant drugs: a retrospective multi-center study. J Clin Biochem Nutr. 2021;69(2):222-228. https:\/\/doi.org\/10.3164\/jcbn.20-140.","journal-title":"J Clin Biochem Nutr."},{"key":"10425_CR11","doi-asserted-by":"publisher","unstructured":"Alcal\u00e1-Gonz\u00e1lez LG, Jim\u00e9nez C, Cortina V, et al. Severity of gastrointestinal bleeding is similar between patients receiving direct oral anticoagulants or vitamin K antagonists. Rev Esp Enferm Dig. 2022;114(10):599\u2013604. https:\/\/doi.org\/10.17235\/reed.2022.8388\/2021.","DOI":"10.17235\/reed.2022.8388\/2021"},{"key":"10425_CR12","doi-asserted-by":"publisher","unstructured":"Solakoglu T, Koseoglu H, Kucukmetin NT, Akar M, Mete R. Effect of Direct-acting Oral Anticoagulants and Warfarin on Hospital Outcomes in Upper Gastrointestinal Bleeding. J Coll Physicians Surg--Pak JCPSP. 2022;32(10):1266\u20131271. https:\/\/doi.org\/10.29271\/jcpsp.2022.10.1266.","DOI":"10.29271\/jcpsp.2022.10.1266"},{"issue":"1","key":"10425_CR13","doi-asserted-by":"publisher","first-page":"16795","DOI":"10.1038\/s41598-022-21166-8","volume":"12","author":"LS Chang","year":"2022","unstructured":"Chang LS, Nishida T, Hosokawa K, et al. Impact of anticoagulants on the clinical outcomes of colonic diverticular bleeding comparing warfarin and direct oral anticoagulants. Sci Rep. 2022;12(1):16795. https:\/\/doi.org\/10.1038\/s41598-022-21166-8.","journal-title":"Sci Rep."},{"key":"10425_CR14","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2147\/CLEP.S91125","volume":"7","author":"M Schmidt","year":"2015","unstructured":"Schmidt M, Schmidt SAJ, Sandegaard JL, Ehrenstein V, Pedersen L, S\u00f8rensen HT. The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol. 2015;7:449-490. https:\/\/doi.org\/10.2147\/CLEP.S91125.","journal-title":"Clin Epidemiol."},{"issue":"3","key":"10425_CR15","doi-asserted-by":"publisher","first-page":"149","DOI":"10.3109\/14017431.2012.673728","volume":"46","author":"TA Rix","year":"2012","unstructured":"Rix TA, Riahi S, Overvad K, Lundbye-Christensen S, Schmidt EB, Joensen AM. Validity of the diagnoses atrial fibrillation and atrial flutter in a Danish patient registry. Scand Cardiovasc J SCJ. 2012;46(3):149-153. https:\/\/doi.org\/10.3109\/14017431.2012.673728.","journal-title":"Scand Cardiovasc J SCJ."},{"issue":"7 Suppl","key":"10425_CR16","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1177\/1403494810394717","volume":"39","author":"HW Kildemoes","year":"2011","unstructured":"Kildemoes HW, S\u00f8rensen HT, Hallas J. The Danish National Prescription Registry. Scand J Public Health. 2011;39(7 Suppl):38-41. https:\/\/doi.org\/10.1177\/1403494810394717.","journal-title":"Scand J Public Health."},{"issue":"7 Suppl","key":"10425_CR17","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1177\/1403494811399958","volume":"39","author":"K Helweg-Larsen","year":"2011","unstructured":"Helweg-Larsen K. The Danish Register of Causes of Death. Scand J Public Health. 2011;39(7 Suppl):26-29. https:\/\/doi.org\/10.1177\/1403494811399958.","journal-title":"Scand J Public Health."},{"key":"10425_CR18","doi-asserted-by":"publisher","unstructured":"Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost JTH. 2005;3(4):692\u2013694. https:\/\/doi.org\/10.1111\/j.1538-7836.2005.01204.x.","DOI":"10.1111\/j.1538-7836.2005.01204.x"},{"key":"10425_CR19","doi-asserted-by":"publisher","first-page":"d124","DOI":"10.1136\/bmj.d124","volume":"342","author":"JB Olesen","year":"2011","unstructured":"Olesen JB, Lip GYH, Hansen ML, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ. 2011;342:d124. https:\/\/doi.org\/10.1136\/bmj.d124.","journal-title":"BMJ."},{"issue":"11","key":"10425_CR20","doi-asserted-by":"publisher","first-page":"e0310322","DOI":"10.1371\/journal.pone.0310322","volume":"19","author":"GYH Lip","year":"2024","unstructured":"Lip GYH, Benamouzig R, Martin AC, et al. Comparative safety and effectiveness of oral anticoagulants in patients with non-valvular atrial fibrillation and high risk of gastrointestinal bleeding: A nationwide French cohort study. PloS One. 2024;19(11):e0310322. https:\/\/doi.org\/10.1371\/journal.pone.0310322.","journal-title":"PloS One."},{"issue":"11","key":"10425_CR21","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-992. https:\/\/doi.org\/10.1056\/NEJMoa1107039.","journal-title":"N Engl J Med."},{"issue":"2","key":"10425_CR22","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.cgh.2022.06.033","volume":"21","author":"AB Ingason","year":"2023","unstructured":"Ingason AB, Hreinsson JP, Agustsson AS, et al. Warfarin Is Associated With Higher Rates of Upper But Not Lower Gastrointestinal Bleeding Compared with Direct Oral Anticoagulants: A Population-Based Propensity-Weighted Cohort Study. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2023;21(2):347-357.e10. https:\/\/doi.org\/10.1016\/j.cgh.2022.06.033.","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc."},{"key":"10425_CR23","doi-asserted-by":"publisher","unstructured":"Adeboyeje G, Sylwestrzak G, Barron JJ, et al. Major Bleeding Risk During Anticoagulation with Warfarin, Dabigatran, Apixaban, or Rivaroxaban in Patients with Nonvalvular Atrial Fibrillation. J Manag Care Spec Pharm. 2017;23(9):968\u2013978. https:\/\/doi.org\/10.18553\/jmcp.2017.23.9.968.","DOI":"10.18553\/jmcp.2017.23.9.968"},{"issue":"5","key":"10425_CR24","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1053\/j.gastro.2016.12.018","volume":"152","author":"NS Abraham","year":"2017","unstructured":"Abraham NS, Noseworthy PA, Yao X, Sangaralingham LR, Shah ND. Gastrointestinal Safety of Direct Oral Anticoagulants: A Large Population-Based Study. Gastroenterology. 2017;152(5):1014-1022.e1. https:\/\/doi.org\/10.1053\/j.gastro.2016.12.018.","journal-title":"Gastroenterology."},{"issue":"21","key":"10425_CR25","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1161\/CIRCULATIONAHA.110.004747","volume":"123","author":"JW Eikelboom","year":"2011","unstructured":"Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011;123(21):2363-2372. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.110.004747.","journal-title":"Circulation."},{"issue":"21","key":"10425_CR26","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1016\/j.jacc.2015.09.024","volume":"66","author":"MW Sherwood","year":"2015","unstructured":"Sherwood MW, Nessel CC, Hellkamp AS, et al. Gastrointestinal Bleeding in Patients With Atrial Fibrillation Treated With Rivaroxaban or Warfarin: ROCKET AF Trial. J Am Coll Cardiol. 2015;66(21):2271-2281. https:\/\/doi.org\/10.1016\/j.jacc.2015.09.024.","journal-title":"J Am Coll Cardiol."},{"issue":"20","key":"10425_CR27","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1016\/j.jacc.2014.02.549","volume":"63","author":"EM Hylek","year":"2014","unstructured":"Hylek EM, Held C, Alexander JH, et al. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes. J Am Coll Cardiol. 2014;63(20):2141-2147. https:\/\/doi.org\/10.1016\/j.jacc.2014.02.549.","journal-title":"J Am Coll Cardiol."},{"issue":"4","key":"10425_CR28","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1160\/TH14-12-1028","volume":"114","author":"SA Black","year":"2015","unstructured":"Black SA, Cohen AT. Anticoagulation strategies for venous thromboembolism: moving towards a personalised approach. Thromb Haemost. 2015;114(4):660-669. https:\/\/doi.org\/10.1160\/TH14-12-1028.","journal-title":"Thromb Haemost."},{"issue":"2","key":"10425_CR29","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1160\/TH13-02-0150","volume":"110","author":"J Desai","year":"2013","unstructured":"Desai J, Kolb JM, Weitz JI, Aisenberg J. Gastrointestinal bleeding with the new oral anticoagulants--defining the issues and the management strategies. Thromb Haemost. 2013;110(2):205-212. https:\/\/doi.org\/10.1160\/TH13-02-0150.","journal-title":"Thromb Haemost."},{"issue":"6","key":"10425_CR30","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1177\/1756283X17702092","volume":"10","author":"D Deutsch","year":"2017","unstructured":"Deutsch D, Bousti\u00e8re C, Ferrari E, Albaladejo P, Morange PE, Benamouzig R. Direct oral anticoagulants and digestive bleeding: therapeutic management and preventive measures. Ther Adv Gastroenterol. 2017;10(6):495-505. https:\/\/doi.org\/10.1177\/1756283X17702092.","journal-title":"Ther Adv Gastroenterol."},{"issue":"2","key":"10425_CR31","doi-asserted-by":"publisher","first-page":"e200","DOI":"10.1055\/s-0041-1730035","volume":"5","author":"P Zappulla","year":"2021","unstructured":"Zappulla P, Calvi V. Gastrointestinal Bleeding and Direct Oral Anticoagulants among Patients with Atrial Fibrillation: Risk, Prevention, Management, and Quality of Life. TH Open Companion J Thromb Haemost. 2021;5(2):e200-e210. https:\/\/doi.org\/10.1055\/s-0041-1730035.","journal-title":"TH Open Companion J Thromb Haemost."},{"issue":"5","key":"10425_CR32","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1007\/s10557-021-07211-0","volume":"36","author":"R Benamouzig","year":"2022","unstructured":"Benamouzig R, Guenoun M, Deutsch D, Fauchier L. Review Article: Gastrointestinal Bleeding Risk with Direct Oral Anticoagulants. Cardiovasc Drugs Ther. 2022;36(5):973-989. https:\/\/doi.org\/10.1007\/s10557-021-07211-0.","journal-title":"Cardiovasc Drugs Ther."},{"key":"10425_CR33","doi-asserted-by":"publisher","unstructured":"Dongre K, Schmid Y, Nussbaum L, et al. Gastrointestinal bleeding during anticoagulation with direct oral anticoagulants compared to vitamin K antagonists. Glob Cardiol Sci Pract. 2022;2022(3):e202221. https:\/\/doi.org\/10.21542\/gcsp.2022.21.","DOI":"10.21542\/gcsp.2022.21"},{"key":"10425_CR34","doi-asserted-by":"publisher","unstructured":"Ullah N, Arif W, Khan MB, et al. Comparative Outcomes of Warfarin vs. Direct Oral Anticoagulants (DOACs) in Anticoagulant-Related Gastrointestinal Bleeding: A Single-Center Study. Cureus. 2024;16(12):e74931. https:\/\/doi.org\/10.7759\/cureus.74931.","DOI":"10.7759\/cureus.74931"},{"key":"10425_CR35","doi-asserted-by":"publisher","unstructured":"Brigida M, Di Caro S, Petruzziello C, et al. Vitamin-K Antagonists vs. Direct Oral Anticoagulants on Severity of Upper Gastrointestinal Bleeding: A Retrospective Analysis of Italian and UK Data. J Clin Med. 2022;11(21):6382. https:\/\/doi.org\/10.3390\/jcm11216382.","DOI":"10.3390\/jcm11216382"},{"issue":"6","key":"10425_CR36","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1016\/j.chest.2016.07.013","volume":"150","author":"PA Noseworthy","year":"2016","unstructured":"Noseworthy PA, Yao X, Abraham NS, Sangaralingham LR, McBane RD, Shah ND. Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Nonvalvular Atrial Fibrillation. Chest. 2016;150(6):1302-1312. https:\/\/doi.org\/10.1016\/j.chest.2016.07.013.","journal-title":"Chest."},{"issue":"1","key":"10425_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5837\/bjc.2022.001","volume":"29","author":"K White","year":"2022","unstructured":"White K, Faruqi U, Cohen AAT. New agents for DOAC reversal: a practical management review. Br J Cardiol. 2022;29(1):1. https:\/\/doi.org\/10.5837\/bjc.2022.001.","journal-title":"Br J Cardiol."},{"issue":"3","key":"10425_CR38","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1001\/archinte.167.3.239","volume":"167","author":"HD White","year":"2007","unstructured":"White HD, Gruber M, Feyzi J, et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med. 2007;167(3):239-245. https:\/\/doi.org\/10.1001\/archinte.167.3.239.","journal-title":"Arch Intern Med."}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-026-10425-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11606-026-10425-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-026-10425-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T18:47:17Z","timestamp":1777488437000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11606-026-10425-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":38,"alternative-id":["10425"],"URL":"https:\/\/doi.org\/10.1007\/s11606-026-10425-3","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]},"assertion":[{"value":"11 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human Ethics and Consent to Participate"}},{"value":"None of the authors have any conflicts of interest related to this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}